Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 3
2011 2
2012 2
2013 4
2014 4
2015 1
2016 1
2017 2
2018 7
2019 2
2021 1
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T. van Montfoort N, et al. Among authors: sluijter m. Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29. Cell. 2018. PMID: 30503208 Free PMC article.
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, Sluijter M, Ruano D, González-Prieto R, Verlaan-de Vries M, Rip J, Arens R, de Miranda NFCC, Hawinkels LJAC, van Hall T, Vertegaal ACO. Kumar S, et al. Among authors: sluijter m. Gut. 2022 Nov;71(11):2266-2283. doi: 10.1136/gutjnl-2021-324834. Epub 2022 Jan 24. Gut. 2022. PMID: 35074907 Free PMC article.
Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Groeneveldt C, van Ginkel JQ, Kinderman P, Sluijter M, Griffioen L, Labrie C, van den Wollenberg DJM, Hoeben RC, van der Burg SH, Ten Dijke P, Hawinkels LJAC, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: sluijter m. Cancer Res Commun. 2023 Feb 23;3(2):325-337. doi: 10.1158/2767-9764.CRC-23-0019. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36860656 Free PMC article.
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.
Middelburg J, Sluijter M, Schaap G, Göynük B, Lloyd K, Ovcinnikovs V, Zom GG, Marijnissen RJ, Groeneveldt C, Griffioen L, Sandker GGW, Heskamp S, van der Burg SH, Arakelian T, Ossendorp F, Arens R, Schuurman J, Kemper K, van Hall T. Middelburg J, et al. Among authors: sluijter m. Nat Commun. 2024 Jan 2;15(1):48. doi: 10.1038/s41467-023-44308-6. Nat Commun. 2024. PMID: 38167722 Free PMC article.
The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent.
Middelburg J, Ghaffari S, Schoufour TAW, Sluijter M, Schaap G, Göynük B, Sala BM, Al-Tamimi L, Scheeren F, Franken KLMC, Akkermans JJLL, Cabukusta B, Joosten SA, Derksen I, Neefjes J, van der Burg SH, Achour A, Wijdeven RHM, Weidanz J, van Hall T. Middelburg J, et al. Among authors: sluijter m. Cell Rep. 2023 Dec 26;42(12):113516. doi: 10.1016/j.celrep.2023.113516. Epub 2023 Dec 3. Cell Rep. 2023. PMID: 38048225 Free article.
Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
Groeneveldt C, Kinderman P, van Stigt Thans JJC, Labrie C, Griffioen L, Sluijter M, van den Wollenberg DJM, Hoeben RC, den Haan JMM, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: sluijter m. J Immunother Cancer. 2022 Jul;10(7):e004464. doi: 10.1136/jitc-2021-004464. J Immunother Cancer. 2022. PMID: 35853671 Free PMC article.
In vivo modelling of cutaneous T-cell lymphoma: The role of SOCS1.
Luo Y, Vermeer MH, de Gruijl FR, Zoutman WH, Sluijter M, van Hall T, Tensen CP. Luo Y, et al. Among authors: sluijter m. Front Oncol. 2022 Nov 24;12:1031052. doi: 10.3389/fonc.2022.1031052. eCollection 2022. Front Oncol. 2022. PMID: 36505769 Free PMC article.
Inhibition of CSF-1R supports T-cell mediated melanoma therapy.
Sluijter M, van der Sluis TC, van der Velden PA, Versluis M, West BL, van der Burg SH, van Hall T. Sluijter M, et al. PLoS One. 2014 Aug 11;9(8):e104230. doi: 10.1371/journal.pone.0104230. eCollection 2014. PLoS One. 2014. PMID: 25110953 Free PMC article.
NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division.
Borst L, Sluijter M, Sturm G, Charoentong P, Santegoets SJ, van Gulijk M, van Elsas MJ, Groeneveldt C, van Montfoort N, Finotello F, Trajanoski Z, Kiełbasa SM, van der Burg SH, van Hall T. Borst L, et al. Among authors: sluijter m. Int J Cancer. 2022 Feb 15;150(4):688-704. doi: 10.1002/ijc.33859. Epub 2021 Nov 10. Int J Cancer. 2022. PMID: 34716584 Free PMC article.
34 results